The developer says that its rheumatoid arthritis candidate CH-4051 failed to outperform the standard of care for the disease in a mid-stage study, forcing it to ax the program.
A newly formed contract research organization in California is hoping to set itself apart from competitors by focusing the bulk of its work on combating pediatric and orphan diseases.
Lundbeck is touting mid-stage data underscoring the effectiveness of its experimental Alzheimer's drug Lu AE58054 for improving cognition and the quality of life for patients.
This morning, Flexion announced that they hit the proof-of-concept stage as planned. Top-line results demonstrated that the intra-articularly delivered FX005 hit its primary endpoint on pain relief and function among osteoarthritis patients.
Over the long Memorial Day, weekend Regeneron Pharmaceuticals ($REGN) and Sanofi ($SNY) added to their stockpile of promising mid-stage data for their PCSK9 drug, which is designed to slash levels of "bad" LDL-cholesterol.
Vertex shares took a nasty tumble this morning, freefalling 18% on the news that the company was forced to revise the data on its closely watched cystic fibrosis combo therapy after learning that the initial interim data report had been bungled.
The Needham, MA-based company's CDX-011 consists of an antibody targeted to the GPNMB protein and an attached chemotherapy agent that is supposed to hit tumor cells with a killer punch.
While the CEO tried to put the data in context, offering reasons for optimism for a planned late-stage study of the lead program, investors watched the stock price crater more than 50% after the news hit.
Based on the findings published in Quintiles' annual "New Health Report," payers want to get the ball rolling sooner to get drugs approved faster.
Halo wants to launch a Phase II for HT-100, an oral drug designed to reduce fibrosis and promote healthy muscle fiber regeneration in DMD patients, in the second half of this year.